Tesamorelin

FDA Approved

Growth Hormone

An FDA-approved GHRH analog that reduces visceral adipose tissue and improves body composition, particularly in lipodystrophy.

Administration

Subcutaneous injection

Dosage Range

2 mg daily

Mechanism of Action

Tesamorelin stimulates the pituitary gland to produce and release growth hormone through GHRH receptor activation, specifically targeting visceral fat reduction while preserving subcutaneous fat and lean mass.

Clinical Benefits

Reduces visceral abdominal fat

Improves body composition

Enhances cognitive function

Reduces liver fat (NAFLD)

Improves lipid profiles

Clinical Evidence

FDA-approved as Egrifta for HIV-associated lipodystrophy. Clinical trials demonstrate 15-18% reduction in visceral adipose tissue. Studies show cognitive improvement and NAFLD reduction.

Side Effects

Injection site reactions

Joint pain

Peripheral edema

Glucose intolerance

Contraindications

Active cancer

Pregnancy

Disrupted hypothalamic-pituitary axis

Hypersensitivity to GHRH

Related Peptides in Growth Hormone

CJC-1295/Ipamorelin

A powerful growth hormone releasing combination that stimulates natural GH production for anti-aging, muscle growth, and fat loss.

Sermorelin

A GHRH analog that stimulates natural growth hormone production, widely used for anti-aging and growth hormone optimization.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.